Trial Profile
Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Alemtuzumab; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 25 Aug 2021 Status changed from active, no longer recruiting to completed.
- 19 Feb 2020 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2020.